Prevenção da neutropenia febril nos diversos tipos de tumores durante o tratamento oncológico

Referências

1. Fietz, T et al. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR, Current Medical Research and Opinion (accepted), DOI: 10.1080/03007995.2018.1560200.

2. Wuerstlein, R et al. Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against
   Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients, Breast Care, 2020 (online) DOI: 10.1159/000506622

3. Bondarenko, I et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy, BMC Cancer, 2013, 13: 386.

4. Clark, O et al. Revisão sistemática e análise de custo-minimização de lipegfilgrastim na profilaxia da neutropenia e da neutropenia febril relacionada à quimioterapia citotóxica. J Bras Econ Saúde, 2016; 8(3): 242-250.